Jasper Therapeutics COO buys convertible preferred stock
Jasper Therapeutics, Inc. reports that Chief Operating Officer Matthew E. Ros purchased 881 shares of Non-Voting Convertible Preferred Stock on July 20, 2026 in a private placement under a securities purchase agreement.
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. reports that Chief Operating Officer Matthew E. Ros purchased 881 shares of Non-Voting Convertible Preferred Stock on July 20, 2026 in a private placement under a securities purchase agreement. Each preferred share is automatically convertible into 61 shares of Voting Common Stock after stockholder approval, subject to a holder-selected 4.9%–19.9% beneficial ownership cap, with no expiration.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 881 shares
Net Buy
1 txn
Insider
Ros Matthew E
Role
Chief Operating Officer
Bought
881 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Non-Voting Convertible Preferred Stock F1, F2 | 881 | -- | -- |
Holdings After Transaction:
Non-Voting Convertible Preferred Stock — 881 contracts (Direct)
Footnotes (2)
- F1. On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026.
- F2. On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.
Key Figures
Preferred shares purchased: 881 shares
Underlying common shares: 53,741 shares
Conversion ratio: 61
+1 more
4 metrics
Preferred shares purchased
881 shares
Non-Voting Convertible Preferred Stock acquired on July 20, 2026
Underlying common shares
53,741 shares
Voting Common Stock issuable upon conversion of reported preferred shares
Conversion ratio
61
Each preferred share converts into 61 shares of Voting Common Stock
Beneficial ownership cap range
4.9%–19.9%
Holder selects maximum post-conversion ownership percentage within this range
Key Terms
Non-Voting Convertible Preferred Stock, securities purchase agreement, accredited investors, beneficially own
4 terms
Non-Voting Convertible Preferred Stock financial
"purchased 881 shares of Non-Voting Convertible Preferred Stock in a private placement"
A non-voting convertible preferred stock is a share that normally pays a fixed dividend and takes priority over common stock for payouts, but does not grant the holder the right to vote on corporate matters. It can be exchanged later for a set number of common shares, offering the potential to participate in price gains without immediate control—like holding a high-yield loan that can be turned into equity, which matters to investors weighing steady income, upside potential, and possible dilution of ownership.
securities purchase agreement financial
"entered into a securities purchase agreement with certain accredited investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
accredited investors financial
"entered into a securities purchase agreement with certain accredited investors"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
beneficially own financial
"would beneficially own more than a specified percentage of Voting Common Stock"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider purchase did Jasper Therapeutics (JSPR) disclose for its COO?
Jasper Therapeutics disclosed that Chief Operating Officer Matthew E. Ros purchased 881 shares of Non-Voting Convertible Preferred Stock on July 20, 2026. The purchase occurred in a private placement under a securities purchase agreement with the company and other accredited investors.
What type of security did JSPR's COO acquire and how can it convert?
The COO acquired Non-Voting Convertible Preferred Stock61 shares of Voting Common Stock on the third business day, subject to specified ownership limitations, and the preferred stock has no expiration date.
What ownership limits apply to the JSPR preferred stock conversion?
A holder cannot convert preferred stock if it would cause them to beneficially own more than a specified percentage of Voting Common Stock. That percentage must be set by the holder between 4.9% and 19.9% of shares outstanding immediately after conversion.
Was the COO's JSPR transaction made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and no footnote states the trade was under a Rule 10b5-1 plan. The transaction is therefore reported as a regular private placement purchase rather than as part of a pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
